This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Alnylam Pharmaceuticals, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: The Innovations of Jonathan Edward Farley
Introduction
Jonathan Edward Farley is a notable inventor based in Boston, MA. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic agents targeting neurodegenerative diseases. His work has the potential to impact the lives of many individuals suffering from conditions such as Alzheimer's disease.
Latest Patents
Farley's most recent patent is titled "Microtubule associated protein Tau (MAPT) iRNA agent compositions and methods of use thereof." This patent relates to double-stranded ribonucleic acid interference (dsRNAi) agents and compositions that specifically target the microtubule-associated protein tau (MAPT) gene. The invention outlines methods for inhibiting the expression of the MAPT gene and offers potential treatments for various tauopathies, including Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy.
Career Highlights
Jonathan Edward Farley is currently employed at Alnylam Pharmaceuticals, Inc., where he continues to advance his research in RNA interference technologies. His innovative work in this area has garnered attention and recognition within the scientific community.
Collaborations
Farley collaborates with esteemed colleagues, including Mark K Schlegel and James D McIninch, who contribute to the research and development of his projects. Their combined expertise enhances the potential for groundbreaking discoveries in the field of neurodegenerative disease treatment.
Conclusion
Jonathan Edward Farley is a pioneering inventor whose work in RNA interference has the potential to transform the treatment landscape for tau-associated diseases. His contributions to biotechnology exemplify the importance of innovation in addressing complex health challenges.